Formed in 2014, Spectromics is a science-focused, venture-backed business established specifically to exploit this novel and proprietary technology from The University of Manchester.

The company has core skills in microbiology, physics, clinical chemistry, microfluidics, engineering and mathematics.

Game-changing and highly differentiated, the technology will initially be used to report antimicrobial susceptibility within minutes at the point of prescription in primary care settings. Later the company intends to evaluate the technology as a high throughput susceptibility platform for use in diagnostic laboratories and in anti-infective drug development/clinical trial recruitment.

Our aim is to make the Spectromics susceptibility test a method of choice for testing where minutes matter and the right drug is essential, no matter whether the patient has a minor infection or a life threatening condition.

As commercial systems develop, we envisage working with partner organisations to exploit our innovative technology globally.